Recurrent fibroblast growth factor receptor3 fusion glioblastoma treated with pemigatinib: A case report and review of the literature.
Journal
Neuro-oncology advances
Series/Report No.
Neuro-Oncology Advances
Journal Volume
6
Journal Issue
1
ISSN
2632-2498
Date Issued
2024
Author(s)
Abstract
This study presents an evaluation of pemigatinib, a selective inhibitor of FGFR1-3, in the management of recurrent FGFR3 fusion glioblastoma, underlining its potential as a precision therapy.Introduced in a 53-year-old man after standard therapies failed and genomic profiling identified an FGFR3-TACC3 fusion, pemigatinib induced a partial disease response and neurological improvement but also posed a financial burden.The case emphasizes the role of precision medicine in neurooncology, and supports further research into the integration of pemigatinib into glioblastoma treatment protocols.Glioblastoma (GB), the most aggressive and common malignant brain tumor in adults, has a poor prognosis.The 5-year relative survival rate is less than 6%.GB has been a difficult disease due to its high recurrent rate even after multimodality treatment, including gross total resection, and concurrent temozolomide chemoradiotherapy (CCRT).After local recurrence, subsequent management has little benefit.Systemic therapy-bevacizumab was granted by US Food and Drug Administration (FDA) approval for relapsed GB.It only provided improved progression-free survival.The 6-month overall survival rate was 57%. 1 Advanced techniques like next-generation sequencing (NGS) have led to a growing focus on glioma's molecular profiles. 2Distinct genetic mutations involve genes like TP53, TERT, PTEN, and fibroblast growth factor receptor (FGFR).The integration of NGS into GB research and care is guiding us towards a new era of precision medicine.Pemigatinib, a kinase inhibitor used to treat locally advanced or metastatic, unresectable cholangiocarcinoma in adults by inhibiting FGFR1, FGFR2, and FGFR3, has been approved by the FDA.It was also used for the patients with previously treated CNS tumors in the phase II trial latterly. 3Herein, the study presented a patient with FGFR3 fusion GB who was treated with pemigatinib and achieved a durable disease response.
Subjects
FGFR3 fusion
neuro-oncology
pemigatinib
precision medicine
recurrent glioblastoma
targeted therapy
SDGs
Publisher
Oxford University Press
Type
journal article